These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 36632569)
1. Corrigendum to: Epigenetic dysregulation in meningiomas. Neurooncol Adv; 2023; 5(1):vdac190. PubMed ID: 36632569 [TBL] [Abstract][Full Text] [Related]
2. Erratum: This is a corrigendum to: Kumthekar et al, A multi-institutional phase II trial of bevacizumab for recurrent and refractory meningioma, Neuro-Oncology Advances, Volume 4, Issue 1, January-December 2022, vdac123, https://doi.org/10.1093/noajnl/vdac123. Neurooncol Adv; 2023; 5(1):vdad103. PubMed ID: 37664526 [TBL] [Abstract][Full Text] [Related]
3. Corrigendum to: ABCB1 inhibition provides a novel therapeutic target to block TWIST1-induced migration in medulloblastoma. Nasir A; Cardall A; Othman RT; Nicolaou N; Lourdusamy A; Linke F; Onion D; Ryzhova M; Cameron H; Valente C; Ritchie A; Korshunov A; Pfister SM; Grabowska AM; Kerr ID; Coyle B Neurooncol Adv; 2021; 3(1):vdab155. PubMed ID: 34988447 [TBL] [Abstract][Full Text] [Related]
4. Corrigendum to: Molecular alterations associated with improved outcome in patients with glioblastoma treated with Tumor-Treating Fields. Neurooncol Adv; 2022; 4(1):vdac164. PubMed ID: 36325375 [TBL] [Abstract][Full Text] [Related]
5. Corrigendum to: Leveraging the CSF proteome toward minimally-invasive diagnostics surveillance of brain malignancies. Neurooncol Adv; 2023; 5(1):vdad019. PubMed ID: 36923271 [TBL] [Abstract][Full Text] [Related]
6. Correction to: Effect of bevacizumab on refractory meningiomas: 3D volumetric growth rate versus response assessment in neuro-oncology criteria. Neurooncol Adv; 2024; 6(1):vdae164. PubMed ID: 39371260 [TBL] [Abstract][Full Text] [Related]
7. Corrigendum to: Generation of immunocompetent syngeneic allograft mouse models for pediatric diffuse midline glioma. Neurooncol Adv; 2023; 5(1):vdad072. PubMed ID: 37303863 [TBL] [Abstract][Full Text] [Related]
8. Corrigendum to: A phase II study of laser interstitial thermal therapy combined with doxorubicin in patients with recurrent glioblastoma. Butt OH; Zhou AY; Huang J; Leidig WA; Silberstein AE; Chheda MG; Johanns TM; Ansstas G; Liu J; Talcott G; Nakiwala R; Shimony JS; Kim AH; Leuthardt EC; Tran DD; Campian JL Neurooncol Adv; 2022; 4(1):vdac042. PubMed ID: 35505674 [TBL] [Abstract][Full Text] [Related]
9. Corrigendum to: Surgery versus radiosurgery for vestibular schwannoma: Shared decision making in a multidisciplinary clinic. Neurooncol Adv; 2024; 6(1):vdae011. PubMed ID: 38312229 [TBL] [Abstract][Full Text] [Related]
10. Corrigendum to: Impact of lymphopenia on survival for elderly patients with glioblastoma: A secondary analysis of the CCTG CE.6 (EORTC 26062-22061, TROG 08.02) randomized clinical trial. Song AJ; Ding K; Alnahhas I; Laperriere NJ; Perry J; Mason WP; Winch C; O'Callaghan CJ; Menten JJ; Brandes AA; Phillips C; Fay MF; Nishikawa R; Osoba D; Cairncross JG; Roa W; Wick W; Shi W Neurooncol Adv; 2022; 4(1):vdac011. PubMed ID: 35098127 [TBL] [Abstract][Full Text] [Related]
11. Corrigendum to: The long non-coding RNA Neurooncol Adv; 2023; 5(1):vdad051. PubMed ID: 37152807 [TBL] [Abstract][Full Text] [Related]
12. Corrigendum to: Impact of extent of resection on outcome from glioblastoma using the RANO resect group classification system: a retrospective, population-based cohort study. Neurooncol Adv; 2023; 5(1):vdad155. PubMed ID: 38077211 [TBL] [Abstract][Full Text] [Related]
13. Corrigendum to: Clinical utility of whole-genome DNA methylation profiling as a primary molecular diagnostic assay for central nervous system tumors-A prospective study and guidelines for clinical testing. Neurooncol Adv; 2023; 5(1):vdad114. PubMed ID: 37750101 [TBL] [Abstract][Full Text] [Related]
14. Corrigendum: An Overview of Managements in Meningiomas. Zhao L; Zhao W; Hou Y; Wen C; Wang J; Wu P; Guo Z Front Oncol; 2020; 10():599431. PubMed ID: 33072614 [TBL] [Abstract][Full Text] [Related]
15. Corrigendum: Identification and management of aggressive meningiomas. Patel B; Desai R; Pugazenthi S; Butt OH; Huang J; Kim AH Front Oncol; 2022; 12():1107271. PubMed ID: 36582787 [TBL] [Abstract][Full Text] [Related]
16. Erratum to: Targeting the TREM1-positive myeloid microenvironment in glioblastoma. Neurooncol Adv; 2023; 5(1):vdac189. PubMed ID: 36632568 [TBL] [Abstract][Full Text] [Related]
17. Corrigendum to: Routine imaging of the preterm neonatal brain. Paediatr Child Health; 2021 Jul; 26(4):259. PubMed ID: 34131460 [TBL] [Abstract][Full Text] [Related]
18. Erratum to: Prognostic value of Neurooncol Adv; 2022; 4(1):vdac069. PubMed ID: 35669014 [TBL] [Abstract][Full Text] [Related]
19. Corrigendum: Metabolism and Epigenetic Interplay in Cancer: Regulation and Putative Therapeutic Targets. Miranda-Gonçalves V; Lameirinhas A; Henrique R; Jerónimo C Front Genet; 2019; 10():784. PubMed ID: 31543902 [TBL] [Abstract][Full Text] [Related]
20. Corrigendum: Reduced Glutamate in the Medial Prefrontal Cortex Is Associated With Emotional and Cognitive Dysregulation in People With Chronic Pain. Naylor B; Hesam-Shariati N; McAuley JH; Boag S; Newton-John T; Rae CD; Gustin SM Front Neurol; 2022; 13():872851. PubMed ID: 35370916 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]